ArticleArthritis care & research2024
Decline in Incidence of Extra-Articular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study.
Article in Arthritis care & research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Menopause status and its role in incident Alzheimer's disease and related dementias, rheumatoid arthritis (RA) disease severity, and overall mortality in women with RA.Seminars in arthritis and rheumatism · 2026Article
- Comparative analysis of extra-articular manifestations in seronegative and seropositive rheumatoid arthritis patients: a 6-year retrospective study in a tertiary care center.Clinical rheumatology · 2026Article
- Extra-articular rheumatoid arthritis: example of RA-associated interstitial lung disease.EULAR rheumatology open · 2026Review
- Long-Term Outcomes in Seronegative Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Extensive Subcutaneous Rheumatoid Nodules Reflecting High Burden of Disease Activity.Mediterranean journal of rheumatology · 2026Article
- Comment on "Methotrexate-Induced Accelerated Nodulosis: A Case Series".Mediterranean journal of rheumatology · 2026Article
- Systemic inflammation and extra-articular manifestations in rheumatoid arthritis: a cross-sectional study.Frontiers in medicine · 2026Article
- Carpal Tunnel Syndrome as an Early Underrecognized Feature of Rheumatoid Arthritis: A Population-Based Study of Carpal Tunnel Syndrome Occurrence Before and After Rheumatoid Arthritis Incidence.Arthritis care & research · 2025Article
- Rheumatoid vasculitis presenting in the absence of rheumatoid arthritis: a case-based review.Rheumatology international · 2025Review
- Autoantibodies as prognostic markers in rheumatoid arthritis.Journal of translational autoimmunity · 2025Review
- Mortality and Predictive Factors for Death Following the Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Retrospective, Long-Term Follow-Up Study.Journal of clinical medicine · 2025Article
- High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions.Rheumatology and therapy · 2025Article
- Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.Current treatment options in rheumatology · 2024Article
- Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years.Frontiers in medicine · 2024Review
- Recent Advances in Rheumatology.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe focus of this study was to assess changes in the cumulative incidence of extra-articular manifestations of rheumatoid arthritis (ExRAs) and associated mortality risk.
methodsThis study evaluated trends in occurrence of ExRAs using a population-based inception cohort that included all adult patients with incident rheumatoid arthritis (RA) from 1985 through 2014 meeting the 1987 American College of Rheumatology criteria. Patients were divided into two cohorts based on the incidence date of RA, 1985 to 1999 and 2000 to 2014. The occurrence of ExRAs was determined by manual chart review, and the 10-year cumulative incidence was estimated for each ExRA in both cohorts. Cox proportional hazard models were used to determine associations between specific demographic and RA disease characteristics and ExRAs and between ExRAs and mortality.
resultsThere were 907 patients included, 296 in the 1985 to 1999 cohort and 611 in the 2000 to 2014 cohort. The 10-year cumulative incidence of any ExRA decreased significantly between the earlier and later cohorts (45.1% vs 31.6%, P < 0.001). This was largely driven by significant declines in subcutaneous rheumatoid nodules (30.9% vs 15.8%, P < 0.001) and nonsevere ExRAs (41.4% vs 28.8%, P = 0.001). Identified risk factors for the development of any ExRAs include rheumatoid factor positivity (hazard ratio [HR] 2.02, 95% confidence interval [CI] 1.43-2.86) and current smoking (HR 1.61, 95% CI 1.10-2.34). Mortality was increased in patients with either nonsevere (HR 1.83, 95% CI 1.18-2.85) or severe ExRAs (HR 3.05, 95% CI 1.44-6.49).
conclusionsThe incidence of ExRAs has decreased over time. Mortality remains increased in patients with ExRAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.